Ensurge Micropower ASA - Registration of Share Capital Increase

Oslo, 26 February 2024 

Reference is made to the announcement by Ensurge Micropower ASA (the "Company") on 20 February 2024 regarding a successful private placement of shares ("Private Placement"), through an allocation of 233,468,885 new shares for total gross proceeds of NOK 58,367,221.25. The share capital increase has now been duly registered in the Register of Business Enterprises. Following the share capital increase, the Company's share capital is NOK 269,315,774.30 divided into 2,693,157,743 shares, each share having a par value of NOK 0.10. 

About Ensurge Micropower: 
Ensurge is Energizing Innovation (TM) with the first ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery for the 1 to 100 milliampere-hour (mAh) class of wearable devices, connected sensors, and beyond. The innovative Ensurge Microbattery enables energy-dense rechargeable products that are ideal for form-factor-constrained applications including hearables (hearing aids and wireless headphones), digital and health wearables, sports and fitness devices, and IoT sensor solutions that use energy harvesting to power everyday things. The company's state-of-the-art manufacturing facility, located in the heart of Silicon Valley, combines patented process technology and materials innovation with the scale of roll-to-roll production methods to bring the advantages of Ensurge technology to established and expanding markets. 

Advisors 
Skandinaviska Enskilda Banken AB (publ) is acting as financial advisor and bookrunner in connection with the Private Placement (the "Manager"). Ræder Bing advokatfirma AS is acting as the Company's legal advisor. Advokatfirmaet Thommessen AS is acting as legal advisor to the Manager. 

For more information, please contact: 
Lars Eikeland, Chief Executive Officer
E-mail: [email protected]

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

You May Also Be Interested In

• StoreClaw Concludes Participation at MDS Singapore Summit 2026
• Yuchen Liu Examines Data-Driven Financial Risk Management for Multinational Enterprises
• HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma